MK2206 + AZD6244 in Patients With Advanced or Metastatic Tumours (010)

• Research type

  Research Study

• Full title

  A Phase I Study of Oral Mk2206 in Combination with Oral AZD6244 in Patients with Locally Advanced or Metastatic Solid Tumours

• IRAS ID

  33239

• Contact name

  Johann De Bono

• Sponsor organisation

  Merck Sharp & Dohme Limited

• Eudract number

  2009-014558-14

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This study will define the maximum tolerated dose of combination therapy with MK2206 and AZD6244 in adult patients with locally advanced or metastatic solid tumours. The study will also look at the safety and effectiveness of the combination therapy. MK-2206 is an experimental drug that blocks a signalling protein called Akt and is being tested for the treatment of cancer. The abnormal activation of Akt is a suspected driver of many human cancers. Drugs that block the abnormal signalling of Akt may thus be a new way of treating cancer. AZD6244 is an experimental drug that works by blocking Mitogen-activated protein kinase 1 (MEK), a biochemical signal that promotes cancer cell growth. Preclinical evidence indicates that combined administration of these compounds could enhance their anticancer properties. About 81 patients will be recruited into the study. Patients will be recruited from sites in the UK and the USA.

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  09/H0801/93

• Date of REC Opinion

  1 Dec 2009

• REC opinion

  Favourable Opinion